Biopharma/Biotech Analyst Chen and Biotech Analyst Watsek, along with Professor Okada of the University of California-San Francisco, Professor of Hematology Diamond at City of Hope and Randall Hyer, former SVP at Moderna, discuss the opportunity for personalized cancers vaccines (relevant companies MRK, MRNA, BNTX, GRTS) on an Analyst/Industry conference call to be held on April 20 at 1 pm. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck, Eisai colorectal cancer study did not meet statistical significance
- Merck, Eisai discontinuing Phase 3 melanoma combination study
- Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Merck, Proxygen enter collaboration, license agreement